- 专利标题: GLYCOTARGETING THERAPEUTICS
-
申请号: US17810573申请日: 2022-07-01
-
公开(公告)号: US20230119325A1公开(公告)日: 2023-04-20
- 发明人: Jeffrey A. Hubbell , David Scott Wilson
- 申请人: École Polytechnique Fédérale de Lausanne (EPFL)
- 申请人地址: CH Lausanne
- 专利权人: École Polytechnique Fédérale de Lausanne (EPFL)
- 当前专利权人: École Polytechnique Fédérale de Lausanne (EPFL)
- 当前专利权人地址: CH Lausanne
- 主分类号: A61K47/54
- IPC分类号: A61K47/54 ; A61K39/35 ; A61K38/28 ; A61K47/58 ; A61K47/60 ; A61K39/385 ; A61K39/00 ; A61K38/38
摘要:
Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
信息查询